Med X Pharma Tech Uk Limited

Active status, founded 6 years ago, 9 employees, revenue range: 0-1m, real address, 2 directors, 1 owner, located in London. Operates in the finance, the processing & manufacturing, the wholesale, the health & social care, the reit, the pharma, the pharma products, the general medical practices, the vaccines, medicaments, diagnostic substances, biotech etc industries.

Cheruparambil Mathew Anoop owns this company. The list of owners was changed six years ago. It is not exhaustive, as only owners with more than twenty five percent of shares are published.

Varghese Mathew, Cheruparambil Mathew Anoop are the directors of this company. The list of directors was changed six years ago.

The company was incorporated six years ago on July 06, 2020.

The registration address is EC1V 2NX, London, MED X PHARMA TECH UK LIMITED, 128 City Road. The address is real address as one company registered at the address.

No export country data available for this company. (non-official data, calculated by Corpsignals)

No import country data available for this company. (non-official data, calculated by Corpsignals)

No port data available for this company. (non-official data, calculated by Corpsignals)

No transport mode data available for this company. (non-official data, calculated by Corpsignals)

The company operates in the finance, the processing & manufacturing, the wholesale, the health & social care, the reit, the pharma, the pharma products, the general medical practices, the vaccines, medicaments, diagnostic substances, biotech etc industries.

It's a micro company as it met two conditions of three: turnover less than £632,000, balance sheet total less than £316,000, employees less than 10. The last reported current assets is £10,000.

CorpSignals sources its data from UK government records including Companies House and HMRC trade data. Data is updated every 24 hours. While we ensure accuracy through automated validation, please refer to original government sources for legal or compliance purposes.